Association of serum bilirubin and promoter variations in HMOX1 and UGT1A1 genes with sporadic colorectal cancer

International Journal of Cancer

Volumn 131, Issue 7, 2012, Pages 1549-1555

  Jirásková, Alena ^a   Novotný, Jan ^a   Novotný, Ladislav ^a   Vodička, Pavel ^a,b   Pardini, Barbara ^b   Naccarati, Alessio ^b   Schwertner, Harvey A ^c   Hubáček, Jaroslav A ^d   Punčochářová, Lucie ^a   Šmerhovský, Zdenek ^a,e   Vítek, Libor ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^c WILFORD HALL MEDICAL CENTER   (United States)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

bilirubin; bilirubin UDP glucuronosyl transferase; colorectal cancer; genetic variations; Gilbert syndrome; heme oxygenase; oxidative stress; UGT1A1

Indexed keywords

BILIRUBIN;

ADULT; AGE; AGED; ALLELE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RISK; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; CZECH REPUBLIC; DISEASE ASSOCIATION; EXPLORATORY RESEARCH; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HMOX1 GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; UGT1A1 GENE;

AGED; ALLELES; BILIRUBIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HEME OXYGENASE-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEX FACTORS;

EID: 84864466536     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27412     Document Type: Article

References (47)

1. Vitek L, Schwertner HA,. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007; 43: 1-57.
2. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN,. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-46.
3. Ryter SW, Alam J, Choi AM,. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86: 583-650.
4. Vitek L, Ostrow JD,. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des 2009; 15: 2869-83.
5. Exner M, Minar E, Wagner O, Schillinger M,. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Rad Biol Med 2004; 37: 1097-104.
6. Schwertner HA, Vitek L,. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008; 198: 1-11.
7. Lin JP, Vitek L, Schwertner HA,. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010; 56: 1535-43.
8. Kikuchi A, Yamaya M, Suzuki S, Yasuda H, Kubo H, Nakayama K, Handa M, Sasaki T, Shibahara S, Sekizawa K, Sasaki H,. Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. Hum Genet 2005; 116: 354-60.
9. Tsuji MH, Yanagawa T, Iwasa S, Tabuchi K, Onizawa K, Bannai S, Toyooka H, Yoshida H,. Heme oxygenase-1 expression in oral squamous cell carcinoma as involved in lymph node metastasis. Cancer Lett 1999; 138: 53-9.
10. Yanagawa T, Omura K, Harada H, Nakaso K, Iwasa S, Koyama Y, Onizawa K, Yusa H, Yoshida H,. Heme oxygenase-1 expression predicts cervical lymph node metastasis of tongue squamous cell carcinomas. Oral Oncol 2004; 40: 21-7.
11. Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS,. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 2006; 243: 47-54.
12. Lo SS, Lin SC, Wu CW, Chen JH, Yeh WI, Chung MY, Lui WY,. Heme oxygenase-1 gene promoter polymorphism is associated with risk of gastric adenocarcinoma and lymphovascular tumor invasion. Ann Surg Oncol 2007; 14: 2250-6.
13. Hu JL, Li ZY, Liu W, Zhang RG, Li GL, Wang T, Ren JH, Wu G,. Polymorphism in heme oxygenase-1 (HO-1) promoter and alcohol are related to the risk of esophageal squamous cell carcinoma on Chinese males. Neoplasma 2010; 57: 86-92.
14. Becker JC, Fukui H, Imai Y, Sekikawa A, Kimura T, Yamagishi H, Yoshitake N, Pohle T, Domschke W, Fujimori T,. Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand J Gastroenterol 2007; 42: 852-8.
15. Zucker SD, Horn PS, Sherman KE,. Serum bilirubin levels in the US population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004; 40: 827-35.
16. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
17. Pardini B, Naccarati A, Polakova V, Smerhovsky Z, Hlavata I, Soucek P, Novotny J, Vodickova L, Tomanova V, Landi S, Vodicka P,. NBN 657del5 heterozygous mutations and colorectal cancer risk in the Czech Republic. Mutat Res 2009; 666: 64-7.
18. Vasen HF, Watson P, Mecklin JP, Lynch HT,. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 2011; 116: 1453-6.
19. Tunstall-Pedoe H,. MONICA monograph and multimedia sourcebook. Geneva: World Health Organization, 2003.
20. Jiraskova A, Lenicek M, Vitek L,. Simultaneous genotyping of microsatellite variations in HMOX1 and UGT1A1 genes using multicolored capillary electrophoresis. Clin Biochem 2010; 43: 697-9.
21. Day IN, Humphries SE,. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem 1994; 222: 389-95.
22. Scheet P, Stephens M,. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 2006; 78: 629-44.
23. Andersen V, Christensen J, Overvad K, Tjonneland A,. Heme oxygenase-1 polymorphism polymorphism is not associated with risk of colorectal cancer: a Danish prospective study. Eur J Gastroenterol Hepatol 2011; 23: 282-5.
24. Rueda B, Oliver J, Robledo G, Lopez-Nevot MA, Balsa A, Pascual-Salcedo D, Gonzalez-Gay, MA, Gonzalez-Escribano MF, Martin J,. HO-1 promoter polymorphism associated with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3953-8.
25. Song F, Li X, Zhang M, Yao P, Yang N, Sun X, Hu FB, Liu L,. Association between heme oxygenase-1 gene promoter polymorphisms and type 2 diabetes in a Chinese population. Am J Epidemiol 2009; 170: 747-56.
26. Buis CI, van der SG, Visser DS, Nolte IM, Hepkema BG, Nijsten M, Slooff MJ, Porte RJ,. Heme oxygenase-1 genotype of the donor is associated with graft survival after liver transplantation. Am J Transplant 2008; 8: 377-85.
27. Was H, Dulak J, Jozkowicz A,. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets 2010; 11: 1551-70.
28. Was H, Sokolowska M, Sierpiniowska A, Dominik P, Skrzypek K, Lackowska B, Pratnicki A, Grochot-Przeczek A, Taha H, Kotlinowski J, Kozakowska M, Mazan A,. Effects of heme oxygenase-1 on induction and development of chemically induced squamous cell carcinoma in mice. Free Rad Biol Med 2011; 51: 1717-26.
29. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G,. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-65.
30. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H, Wadelius M,. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2011; 11: 61-71.
31. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre D, Miran I, Mulot C, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010; 28: 2556-64.
32. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28: 3227-33.
33. ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update 2006; 12: 483-97.
34. Yong M, Schwartz SM, Atkinson C, Makar KW, Thomas SS, Stanczyk FZ, Westerlind KC, Newton KM, Holt VL, Leisenring WM, Lampe JW,. Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States. J Steroid Biochem Mol Biol 2010; 124: 10-8.
35. Muraca M, Fevery J,. Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver. Gastroenteology 1984; 87: 308-13.
36. Duguay Y, McGrath M, Lepine J, Gagne JF, Hankinson SE, Colditz GA, Hunter DJ, Plante M, Têtu B, Bélanger A, Guillemette C, De Vivo I,. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res 2004; 64: 1202-7.
37. Huo D, Kim HJ, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, Niu Q, Sveen L, Fackenthal JD, Fackenthal DL, Das S, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat 2008; 110: 367-76.
38. Karatzas A, Giannatou E, Tzortzis V, Gravas S, Aravantinos E, Moutzouris G, Melekos M, Tsezou A,. Genetic polymorphisms in the UDP- glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men. Cancer Epidemiol 2010; 34: 345-9.
39. Deming SL, Zheng W, Xu WH, Cai Q, Ruan Z, Xiang YB, Shu XO,. UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 563-70.
40. Marnett LJ,. Oxyradicals and DNA damage. Carcinogenesis 2000; 21: 361-70.
41. Di G, Acquaviva R, Lanteri R, Licata F, Licata A, Vanella A,. Nonproteic antioxidant status in plasma of subjects with colon cancer. Exp Biol Med 2003; 228: 525-8.
42. Keshavan P, Schwemberger SJ, Smith DLH, Babcock GF, Zucker SD,. Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization. Int J Cancer 2004; 112: 433-45.
43. Vitek L, Malikova I, Kvasnicka J, Benakova H, Novotny L,. Relationship between serum bilirubin and markers of inflammation and oxidative stress. J Gastroenterol Hepatol 2007; 22: A235.
44. Lanone S, Bloc S, Foresti R, Almolki A, Taille C, Callebert J, Conti M, Goven D, Aubier M, Dureuil B, El-Benna J, Motterlini R, et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 2005; 19: 1890-2.
45. McCarty MF, Barroso-Aranda J, Contreras F,. A two-phase strategy for treatment of oxidant-dependent cancers. Med Hypotheses 2007; 69: 489-96.
46. Keshavan P, Deem TL, Schwemberger SJ, Babcock GF, Cook-Mills JM, Zucker SD,. Unconjugated bilirubin inhibits VCAM-1-mediated transendothelial leukocyte migration. J Immunol 2005; 174: 3709-18.
47. Wu TC,. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007; 67: 6003-6.